#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Recent World Health Organization ( WHO ) evidence reviews , published in the International Journal of Environmental Research and Public Health , have revealed sufficient evidence that sources of transportation noise lead to serious annoyance , sleep disturbance , and cardio-metabolic disorders .
2-1	16-22	Recent	organization[3]	new[3]	_	_
2-2	23-28	World	organization[3]	new[3]	_	_
2-3	29-35	Health	abstract|organization[3]	new|new[3]	coref	2-20[8_0]
2-4	36-48	Organization	organization[3]	new[3]	_	_
2-5	49-50	(	abstract[5]	new[5]	coref	18-11[151_5]
2-6	51-54	WHO	abstract[5]	new[5]	_	_
2-7	55-56	)	abstract[5]	new[5]	_	_
2-8	57-65	evidence	abstract|abstract[5]	new|new[5]	coref	2-25[9_0]
2-9	66-73	reviews	abstract[5]	new[5]	_	_
2-10	74-75	,	_	_	_	_
2-11	76-85	published	_	_	_	_
2-12	86-88	in	_	_	_	_
2-13	89-92	the	organization[6]	new[6]	_	_
2-14	93-106	International	organization[6]	new[6]	_	_
2-15	107-114	Journal	organization[6]	new[6]	_	_
2-16	115-117	of	organization[6]	new[6]	_	_
2-17	118-131	Environmental	organization[6]|organization[7]	new[6]|new[7]	_	_
2-18	132-140	Research	organization[6]|organization[7]	new[6]|new[7]	_	_
2-19	141-144	and	organization[6]	new[6]	_	_
2-20	145-151	Public	organization[6]|abstract[8]	new[6]|giv[8]	coref	3-11[19_8]
2-21	152-158	Health	organization[6]|abstract[8]	new[6]|giv[8]	_	_
2-22	159-160	,	_	_	_	_
2-23	161-165	have	_	_	_	_
2-24	166-174	revealed	_	_	_	_
2-25	175-185	sufficient	abstract[9]	giv[9]	coref	3-3[0_9]
2-26	186-194	evidence	abstract[9]	giv[9]	_	_
2-27	195-199	that	_	_	_	_
2-28	200-207	sources	abstract[10]	new[10]	_	_
2-29	208-210	of	abstract[10]	new[10]	_	_
2-30	211-225	transportation	abstract[10]|abstract|abstract[12]	new[10]|new|new[12]	coref	17-19[145_12]
2-31	226-231	noise	abstract[10]|abstract[12]	new[10]|new[12]	_	_
2-32	232-236	lead	_	_	_	_
2-33	237-239	to	_	_	_	_
2-34	240-247	serious	abstract[13]	new[13]	_	_
2-35	248-257	annoyance	abstract[13]	new[13]	_	_
2-36	258-259	,	_	_	_	_
2-37	260-265	sleep	abstract|abstract[15]	new|new[15]	_	_
2-38	266-277	disturbance	abstract[15]	new[15]	_	_
2-39	278-279	,	_	_	_	_
2-40	280-283	and	_	_	_	_
2-41	284-300	cardio-metabolic	abstract[16]	new[16]	coref	5-6[31_16]
2-42	301-310	disorders	abstract[16]	new[16]	_	_
2-43	311-312	.	_	_	_	_

#Text=Less convincing evidence and no exposure-response information was provided for mental health .
3-1	313-317	Less	_	_	_	_
3-2	318-328	convincing	_	_	_	_
3-3	329-337	evidence	abstract	giv	coref	10-7
3-4	338-341	and	_	_	_	_
3-5	342-344	no	abstract[18]	new[18]	_	_
3-6	345-362	exposure-response	abstract[18]	new[18]	_	_
3-7	363-374	information	abstract[18]	new[18]	_	_
3-8	375-378	was	_	_	_	_
3-9	379-387	provided	_	_	_	_
3-10	388-391	for	_	_	_	_
3-11	392-398	mental	abstract[19]	giv[19]	coref	4-1[20_19]
3-12	399-405	health	abstract[19]	giv[19]	_	_
3-13	406-407	.	_	_	_	_

#Text=Mental health is a perquisite for well-being and participation in social and economic life , with the burden already amounting to about 4 % of the gross domestic product across European Union countries .
4-1	408-414	Mental	abstract[20]	giv[20]	coref	4-4[21_20]
4-2	415-421	health	abstract[20]	giv[20]	_	_
4-3	422-424	is	_	_	_	_
4-4	425-426	a	abstract[21]	giv[21]	coref	7-31[0_21]
4-5	427-437	perquisite	abstract[21]	giv[21]	_	_
4-6	438-441	for	abstract[21]	giv[21]	_	_
4-7	442-452	well-being	abstract[21]|abstract	giv[21]|new	_	_
4-8	453-456	and	abstract[21]	giv[21]	_	_
4-9	457-470	participation	abstract[21]|abstract[23]	giv[21]|new[23]	_	_
4-10	471-473	in	abstract[21]|abstract[23]	giv[21]|new[23]	_	_
4-11	474-480	social	abstract[21]|abstract[23]|abstract[24]	giv[21]|new[23]|new[24]	coref	10-32[80_24]
4-12	481-484	and	abstract[21]|abstract[23]|abstract[24]	giv[21]|new[23]|new[24]	_	_
4-13	485-493	economic	abstract[21]|abstract[23]|abstract[24]	giv[21]|new[23]|new[24]	_	_
4-14	494-498	life	abstract[21]|abstract[23]|abstract[24]	giv[21]|new[23]|new[24]	_	_
4-15	499-500	,	abstract[21]	giv[21]	_	_
4-16	501-505	with	abstract[21]	giv[21]	_	_
4-17	506-509	the	abstract[21]|abstract[25]	giv[21]|new[25]	coref	13-10[109_25]
4-18	510-516	burden	abstract[21]|abstract[25]	giv[21]|new[25]	_	_
4-19	517-524	already	_	_	_	_
4-20	525-534	amounting	_	_	_	_
4-21	535-537	to	_	_	_	_
4-22	538-543	about	quantity[26]	new[26]	_	_
4-23	544-545	4	quantity[26]	new[26]	_	_
4-24	546-547	%	quantity[26]	new[26]	_	_
4-25	548-550	of	quantity[26]	new[26]	_	_
4-26	551-554	the	quantity[26]|abstract[27]	new[26]|new[27]	_	_
4-27	555-560	gross	quantity[26]|abstract[27]	new[26]|new[27]	_	_
4-28	561-569	domestic	quantity[26]|abstract[27]	new[26]|new[27]	_	_
4-29	570-577	product	quantity[26]|abstract[27]	new[26]|new[27]	_	_
4-30	578-584	across	quantity[26]|abstract[27]	new[26]|new[27]	_	_
4-31	585-593	European	quantity[26]|abstract[27]|place[28]|place[29]	new[26]|new[27]|new[28]|new[29]	coref	7-11[46_29]
4-32	594-599	Union	quantity[26]|abstract[27]|place[28]|place[29]	new[26]|new[27]|new[28]|new[29]	_	_
4-33	600-609	countries	quantity[26]|abstract[27]|place[29]	new[26]|new[27]|new[29]	_	_
4-34	610-611	.	_	_	_	_

#Text=Unlike other chronic diseases , mental disorders such as anxiety and depression show an early-life onset , ranging from mild and time-limited to chronic and severe impairments .
5-1	612-618	Unlike	_	_	_	_
5-2	619-624	other	abstract[30]	new[30]	_	_
5-3	625-632	chronic	abstract[30]	new[30]	_	_
5-4	633-641	diseases	abstract[30]	new[30]	_	_
5-5	642-643	,	_	_	_	_
5-6	644-650	mental	abstract[31]	giv[31]	coref	7-8[45_31]
5-7	651-660	disorders	abstract[31]	giv[31]	_	_
5-8	661-665	such	abstract[31]	giv[31]	_	_
5-9	666-668	as	abstract[31]	giv[31]	_	_
5-10	669-676	anxiety	abstract[31]|abstract|abstract[33]	giv[31]|new|new[33]	coref|coref	7-6|7-6[43_33]
5-11	677-680	and	abstract[31]|abstract[33]	giv[31]|new[33]	_	_
5-12	681-691	depression	abstract[31]|abstract[33]|abstract	giv[31]|new[33]|new	coref	10-37
5-13	692-696	show	_	_	_	_
5-14	697-699	an	event[35]	new[35]	ana	7-26[0_35]
5-15	700-710	early-life	event[35]	new[35]	_	_
5-16	711-716	onset	event[35]	new[35]	_	_
5-17	717-718	,	_	_	_	_
5-18	719-726	ranging	_	_	_	_
5-19	727-731	from	_	_	_	_
5-20	732-736	mild	_	_	_	_
5-21	737-740	and	_	_	_	_
5-22	741-753	time-limited	_	_	_	_
5-23	754-756	to	_	_	_	_
5-24	757-764	chronic	abstract[36]	new[36]	_	_
5-25	765-768	and	abstract[36]	new[36]	_	_
5-26	769-775	severe	abstract[36]	new[36]	_	_
5-27	776-787	impairments	abstract[36]	new[36]	_	_
5-28	788-789	.	_	_	_	_

#Text=This feature makes the illness difficult to identify , and therefore , it is often poorly treated and overlooked .
6-1	790-794	This	abstract[37]	new[37]	_	_
6-2	795-802	feature	abstract[37]	new[37]	_	_
6-3	803-808	makes	_	_	_	_
6-4	809-812	the	abstract[38]	new[38]	ana	6-13[0_38]
6-5	813-820	illness	abstract[38]	new[38]	_	_
6-6	821-830	difficult	abstract[38]	new[38]	_	_
6-7	831-833	to	abstract[38]	new[38]	_	_
6-8	834-842	identify	abstract[38]	new[38]	_	_
6-9	843-844	,	_	_	_	_
6-10	845-848	and	_	_	_	_
6-11	849-858	therefore	_	_	_	_
6-12	859-860	,	_	_	_	_
6-13	861-863	it	abstract	giv	_	_
6-14	864-866	is	_	_	_	_
6-15	867-872	often	_	_	_	_
6-16	873-879	poorly	_	_	_	_
6-17	880-887	treated	_	_	_	_
6-18	888-891	and	_	_	_	_
6-19	892-902	overlooked	_	_	_	_
6-20	903-904	.	_	_	_	_

#Text=The 12-month point prevalence of anxiety and depressive disorders in Western countries sums up to 10 % – 14 % on average now , and it has become a public health priority issue around the World in the case of adults and children .
7-1	905-908	The	abstract[41]	new[41]	coref	9-37[69_41]
7-2	909-917	12-month	abstract[41]	new[41]	_	_
7-3	918-923	point	abstract|abstract[41]	new|new[41]	_	_
7-4	924-934	prevalence	abstract[41]	new[41]	_	_
7-5	935-937	of	abstract[41]	new[41]	_	_
7-6	938-945	anxiety	abstract[41]|abstract|abstract[43]	new[41]|giv|giv[43]	coref	10-39
7-7	946-949	and	abstract[41]|abstract[43]	new[41]|giv[43]	_	_
7-8	950-960	depressive	abstract[41]|abstract[43]|abstract|abstract[45]	new[41]|giv[43]|new|giv[45]	coref	9-6[62_45]
7-9	961-970	disorders	abstract[41]|abstract[43]|abstract[45]	new[41]|giv[43]|giv[45]	_	_
7-10	971-973	in	abstract[41]|abstract[43]|abstract[45]	new[41]|giv[43]|giv[45]	_	_
7-11	974-981	Western	abstract[41]|abstract[43]|abstract[45]|place[46]	new[41]|giv[43]|giv[45]|giv[46]	_	_
7-12	982-991	countries	abstract[41]|abstract[43]|abstract[45]|place[46]	new[41]|giv[43]|giv[45]|giv[46]	_	_
7-13	992-996	sums	_	_	_	_
7-14	997-999	up	_	_	_	_
7-15	1000-1002	to	_	_	_	_
7-16	1003-1005	10	quantity[47]	new[47]	_	_
7-17	1006-1007	%	quantity[47]	new[47]	_	_
7-18	1008-1009	–	quantity[47]	new[47]	_	_
7-19	1010-1012	14	quantity[47]|quantity[48]	new[47]|new[48]	_	_
7-20	1013-1014	%	quantity[47]|quantity[48]	new[47]|new[48]	_	_
7-21	1015-1017	on	quantity[47]|quantity[48]	new[47]|new[48]	_	_
7-22	1018-1025	average	quantity[47]|quantity[48]	new[47]|new[48]	_	_
7-23	1026-1029	now	quantity[47]|quantity[48]	new[47]|new[48]	_	_
7-24	1030-1031	,	_	_	_	_
7-25	1032-1035	and	_	_	_	_
7-26	1036-1038	it	event	giv	_	_
7-27	1039-1042	has	_	_	_	_
7-28	1043-1049	become	_	_	_	_
7-29	1050-1051	a	_	_	_	_
7-30	1052-1058	public	_	_	_	_
7-31	1059-1065	health	abstract	giv	coref	10-10[73_0]
7-32	1066-1074	priority	abstract	new	_	_
7-33	1075-1080	issue	_	_	_	_
7-34	1081-1087	around	_	_	_	_
7-35	1088-1091	the	place[52]	new[52]	_	_
7-36	1092-1097	World	place[52]	new[52]	_	_
7-37	1098-1100	in	_	_	_	_
7-38	1101-1104	the	abstract[53]	new[53]	_	_
7-39	1105-1109	case	abstract[53]	new[53]	_	_
7-40	1110-1112	of	abstract[53]	new[53]	_	_
7-41	1113-1119	adults	abstract[53]|person	new[53]|new	_	_
7-42	1120-1123	and	abstract[53]	new[53]	_	_
7-43	1124-1132	children	abstract[53]|person	new[53]|new	_	_
7-44	1133-1134	.	_	_	_	_

#Text=Although the treatment of both conditions is increasing , undertreatment is still prevalent and treatment effectiveness is modest .
8-1	1135-1143	Although	_	_	_	_
8-2	1144-1147	the	abstract[56]	new[56]	coref	8-15[0_56]
8-3	1148-1157	treatment	abstract[56]	new[56]	_	_
8-4	1158-1160	of	abstract[56]	new[56]	_	_
8-5	1161-1165	both	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-6	1166-1176	conditions	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-7	1177-1179	is	_	_	_	_
8-8	1180-1190	increasing	_	_	_	_
8-9	1191-1192	,	_	_	_	_
8-10	1193-1207	undertreatment	abstract	new	_	_
8-11	1208-1210	is	_	_	_	_
8-12	1211-1216	still	_	_	_	_
8-13	1217-1226	prevalent	_	_	_	_
8-14	1227-1230	and	_	_	_	_
8-15	1231-1240	treatment	abstract|abstract[60]	giv|new[60]	coref	9-18[64_0]
8-16	1241-1254	effectiveness	abstract[60]	new[60]	_	_
8-17	1255-1257	is	_	_	_	_
8-18	1258-1264	modest	_	_	_	_
8-19	1265-1266	.	_	_	_	_

#Text=Moreover , the pathway to mental disorders is a complex and interactive process , and over-reliance on individual treatment at the expense of broader “ structural prevention ” approaches has further hindered the successful reduction of disease prevalence .
9-1	1267-1275	Moreover	_	_	_	_
9-2	1276-1277	,	_	_	_	_
9-3	1278-1281	the	abstract[61]	new[61]	coref	9-9[63_61]
9-4	1282-1289	pathway	abstract[61]	new[61]	_	_
9-5	1290-1292	to	abstract[61]	new[61]	_	_
9-6	1293-1299	mental	abstract[61]|abstract[62]	new[61]|giv[62]	coref	10-39[85_62]
9-7	1300-1309	disorders	abstract[61]|abstract[62]	new[61]|giv[62]	_	_
9-8	1310-1312	is	_	_	_	_
9-9	1313-1314	a	abstract[63]	giv[63]	_	_
9-10	1315-1322	complex	abstract[63]	giv[63]	_	_
9-11	1323-1326	and	abstract[63]	giv[63]	_	_
9-12	1327-1338	interactive	abstract[63]	giv[63]	_	_
9-13	1339-1346	process	abstract[63]	giv[63]	_	_
9-14	1347-1348	,	_	_	_	_
9-15	1349-1352	and	_	_	_	_
9-16	1353-1366	over-reliance	_	_	_	_
9-17	1367-1369	on	_	_	_	_
9-18	1370-1380	individual	abstract[64]	giv[64]	_	_
9-19	1381-1390	treatment	abstract[64]	giv[64]	_	_
9-20	1391-1393	at	_	_	_	_
9-21	1394-1397	the	abstract[65]	new[65]	_	_
9-22	1398-1405	expense	abstract[65]	new[65]	_	_
9-23	1406-1408	of	abstract[65]	new[65]	_	_
9-24	1409-1416	broader	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-25	1417-1418	“	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-26	1419-1429	structural	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-27	1430-1440	prevention	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-28	1441-1442	”	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-29	1443-1453	approaches	_	_	_	_
9-30	1454-1457	has	_	_	_	_
9-31	1458-1465	further	_	_	_	_
9-32	1466-1474	hindered	_	_	_	_
9-33	1475-1478	the	abstract[67]	new[67]	_	_
9-34	1479-1489	successful	abstract[67]	new[67]	_	_
9-35	1490-1499	reduction	abstract[67]	new[67]	_	_
9-36	1500-1502	of	abstract[67]	new[67]	_	_
9-37	1503-1510	disease	abstract[67]|abstract|abstract[69]	new[67]|new|giv[69]	coref	13-12
9-38	1511-1521	prevalence	abstract[67]|abstract[69]	new[67]|giv[69]	_	_
9-39	1522-1523	.	_	_	_	_

#Text=It was unfortunate that the WHO evidence review on mental health was hampered mainly by the broad outcome selection , which embraced different levels of severity , from health-related quality of life to clinical outcomes like depression or anxiety disorders .
10-1	1524-1526	It	abstract	new	cata	10-1[0_74]
10-2	1527-1530	was	_	_	_	_
10-3	1531-1542	unfortunate	_	_	_	_
10-4	1543-1547	that	abstract[74]	new[74]	_	_
10-5	1548-1551	the	abstract[72]|abstract[74]	new[72]|new[74]	coref	14-5[116_72]
10-6	1552-1555	WHO	abstract[72]|abstract[74]	new[72]|new[74]	_	_
10-7	1556-1564	evidence	abstract|abstract[72]|abstract[74]	giv|new[72]|new[74]	coref	13-3[107_0]
10-8	1565-1571	review	abstract[72]|abstract[74]	new[72]|new[74]	_	_
10-9	1572-1574	on	abstract[72]|abstract[74]	new[72]|new[74]	_	_
10-10	1575-1581	mental	abstract[72]|abstract[73]|abstract[74]	new[72]|giv[73]|new[74]	coref	12-15[0_73]
10-11	1582-1588	health	abstract[72]|abstract[73]|abstract[74]	new[72]|giv[73]|new[74]	_	_
10-12	1589-1592	was	abstract[74]	new[74]	_	_
10-13	1593-1601	hampered	abstract[74]	new[74]	_	_
10-14	1602-1608	mainly	abstract[74]	new[74]	_	_
10-15	1609-1611	by	_	_	_	_
10-16	1612-1615	the	abstract[76]	new[76]	_	_
10-17	1616-1621	broad	abstract[76]	new[76]	_	_
10-18	1622-1629	outcome	event|abstract[76]	new|new[76]	_	_
10-19	1630-1639	selection	abstract[76]	new[76]	_	_
10-20	1640-1641	,	_	_	_	_
10-21	1642-1647	which	_	_	_	_
10-22	1648-1656	embraced	_	_	_	_
10-23	1657-1666	different	abstract[77]	new[77]	_	_
10-24	1667-1673	levels	abstract[77]	new[77]	_	_
10-25	1674-1676	of	abstract[77]	new[77]	_	_
10-26	1677-1685	severity	abstract[77]|abstract	new[77]|new	_	_
10-27	1686-1687	,	_	_	_	_
10-28	1688-1692	from	_	_	_	_
10-29	1693-1707	health-related	abstract[79]	new[79]	coref	15-11[0_79]
10-30	1708-1715	quality	abstract[79]	new[79]	_	_
10-31	1716-1718	of	abstract[79]	new[79]	_	_
10-32	1719-1723	life	abstract[79]|abstract[80]	new[79]|giv[80]	_	_
10-33	1724-1726	to	abstract[79]|abstract[80]	new[79]|giv[80]	_	_
10-34	1727-1735	clinical	abstract[79]|abstract[80]|event[81]	new[79]|giv[80]|new[81]	coref	11-7[89_81]
10-35	1736-1744	outcomes	abstract[79]|abstract[80]|event[81]	new[79]|giv[80]|new[81]	_	_
10-36	1745-1749	like	abstract[79]|abstract[80]|event[81]	new[79]|giv[80]|new[81]	_	_
10-37	1750-1760	depression	abstract[79]|abstract[80]|event[81]|abstract|abstract[83]	new[79]|giv[80]|new[81]|giv|new[83]	coref|coref	14-32|14-32[125_83]
10-38	1761-1763	or	abstract[79]|abstract[80]|event[81]|abstract[83]	new[79]|giv[80]|new[81]|new[83]	_	_
10-39	1764-1771	anxiety	abstract[79]|abstract[80]|event[81]|abstract[83]|abstract|abstract[85]	new[79]|giv[80]|new[81]|new[83]|giv|giv[85]	coref|coref	14-34[127_85]|17-13
10-40	1772-1781	disorders	abstract[79]|abstract[80]|event[81]|abstract[83]|abstract[85]	new[79]|giv[80]|new[81]|new[83]|giv[85]	_	_
10-41	1782-1783	.	_	_	_	_

#Text=The small number of studies in the sub-section outcomes and the diverse measurement instruments used in the available studies ( symptom questionnaires , clinical diagnoses , psychotropic medication ) prevented the authors from conducting full meta-analyses .
11-1	1784-1787	The	quantity[86]	new[86]	_	_
11-2	1788-1793	small	quantity[86]	new[86]	_	_
11-3	1794-1800	number	quantity[86]	new[86]	_	_
11-4	1801-1803	of	quantity[86]	new[86]	_	_
11-5	1804-1811	studies	quantity[86]|event[87]	new[86]|new[87]	coref	11-17[92_87]
11-6	1812-1814	in	quantity[86]|event[87]	new[86]|new[87]	_	_
11-7	1815-1818	the	quantity[86]|event[87]|event[89]	new[86]|new[87]|giv[89]	coref	12-12[104_89]
11-8	1819-1830	sub-section	quantity[86]|event[87]|place|event[89]	new[86]|new[87]|new|giv[89]	_	_
11-9	1831-1839	outcomes	quantity[86]|event[87]|event[89]	new[86]|new[87]|giv[89]	_	_
11-10	1840-1843	and	quantity[86]|event[87]|event[89]	new[86]|new[87]|giv[89]	_	_
11-11	1844-1847	the	quantity[86]|event[87]|event[89]|abstract[91]	new[86]|new[87]|giv[89]|new[91]	_	_
11-12	1848-1855	diverse	quantity[86]|event[87]|event[89]|abstract[91]	new[86]|new[87]|giv[89]|new[91]	_	_
11-13	1856-1867	measurement	quantity[86]|event[87]|event[89]|abstract|abstract[91]	new[86]|new[87]|giv[89]|new|new[91]	_	_
11-14	1868-1879	instruments	quantity[86]|event[87]|event[89]|abstract[91]	new[86]|new[87]|giv[89]|new[91]	_	_
11-15	1880-1884	used	_	_	_	_
11-16	1885-1887	in	_	_	_	_
11-17	1888-1891	the	event[92]	giv[92]	coref	12-8[102_92]
11-18	1892-1901	available	event[92]	giv[92]	_	_
11-19	1902-1909	studies	event[92]	giv[92]	_	_
11-20	1910-1911	(	_	_	_	_
11-21	1912-1919	symptom	abstract|abstract[94]	new|new[94]	_	_
11-22	1920-1934	questionnaires	abstract[94]	new[94]	_	_
11-23	1935-1936	,	_	_	_	_
11-24	1937-1945	clinical	abstract[95]	new[95]	_	_
11-25	1946-1955	diagnoses	abstract[95]	new[95]	_	_
11-26	1956-1957	,	_	_	_	_
11-27	1958-1970	psychotropic	abstract|abstract[97]	new|new[97]	_	_
11-28	1971-1981	medication	abstract[97]	new[97]	_	_
11-29	1982-1983	)	_	_	_	_
11-30	1984-1993	prevented	_	_	_	_
11-31	1994-1997	the	person[98]	new[98]	_	_
11-32	1998-2005	authors	person[98]	new[98]	_	_
11-33	2006-2010	from	_	_	_	_
11-34	2011-2021	conducting	_	_	_	_
11-35	2022-2026	full	abstract[99]	new[99]	_	_
11-36	2027-2040	meta-analyses	abstract[99]	new[99]	_	_
11-37	2041-2042	.	_	_	_	_

#Text=Clark and Paunovic concluded that there were too few studies of clinically significant mental health outcomes , and studies of large samples were needed .
12-1	2043-2048	Clark	person	new	_	_
12-2	2049-2052	and	_	_	_	_
12-3	2053-2061	Paunovic	person	new	_	_
12-4	2062-2071	concluded	_	_	_	_
12-5	2072-2076	that	_	_	_	_
12-6	2077-2082	there	_	_	_	_
12-7	2083-2087	were	_	_	_	_
12-8	2088-2091	too	event[102]	giv[102]	_	_
12-9	2092-2095	few	event[102]	giv[102]	_	_
12-10	2096-2103	studies	event[102]	giv[102]	_	_
12-11	2104-2106	of	event[102]	giv[102]	_	_
12-12	2107-2117	clinically	event[102]|event[104]	giv[102]|giv[104]	coref	14-24[123_104]
12-13	2118-2129	significant	event[102]|event[104]	giv[102]|giv[104]	_	_
12-14	2130-2136	mental	event[102]|event[104]	giv[102]|giv[104]	_	_
12-15	2137-2143	health	event[102]|abstract|event[104]	giv[102]|giv|giv[104]	coref	14-7
12-16	2144-2152	outcomes	event[102]|event[104]	giv[102]|giv[104]	_	_
12-17	2153-2154	,	_	_	_	_
12-18	2155-2158	and	_	_	_	_
12-19	2159-2166	studies	event[105]	new[105]	coref	14-21[121_105]
12-20	2167-2169	of	event[105]	new[105]	_	_
12-21	2170-2175	large	event[105]|quantity[106]	new[105]|new[106]	_	_
12-22	2176-2183	samples	event[105]|quantity[106]	new[105]|new[106]	_	_
12-23	2184-2188	were	_	_	_	_
12-24	2189-2195	needed	_	_	_	_
12-25	2196-2197	.	_	_	_	_

#Text=However , quantitative evidence is a necessary requirement for burden of disease estimation and setting exposure guidelines .
13-1	2198-2205	However	_	_	_	_
13-2	2206-2207	,	_	_	_	_
13-3	2208-2220	quantitative	abstract[107]	giv[107]	coref	13-6[108_107]
13-4	2221-2229	evidence	abstract[107]	giv[107]	_	_
13-5	2230-2232	is	_	_	_	_
13-6	2233-2234	a	abstract[108]	giv[108]	coref	15-15[0_108]
13-7	2235-2244	necessary	abstract[108]	giv[108]	_	_
13-8	2245-2256	requirement	abstract[108]	giv[108]	_	_
13-9	2257-2260	for	abstract[108]	giv[108]	_	_
13-10	2261-2267	burden	abstract[108]|abstract[109]	giv[108]|giv[109]	_	_
13-11	2268-2270	of	abstract[108]|abstract[109]	giv[108]|giv[109]	_	_
13-12	2271-2278	disease	abstract[108]|abstract[109]|abstract|abstract[111]	giv[108]|giv[109]|giv|new[111]	_	_
13-13	2279-2289	estimation	abstract[108]|abstract[109]|abstract[111]	giv[108]|giv[109]|new[111]	_	_
13-14	2290-2293	and	_	_	_	_
13-15	2294-2301	setting	_	_	_	_
13-16	2302-2310	exposure	abstract|abstract[113]	new|new[113]	coref	17-16[142_0]
13-17	2311-2321	guidelines	abstract[113]	new[113]	_	_
13-18	2322-2323	.	_	_	_	_

#Text=In the meantime ( the mental health review included papers up to October 2015 ) , a sufficient number of new studies on more severe mental health outcomes , such as depression and other mental health disorders , were published .
14-1	2324-2326	In	_	_	_	_
14-2	2327-2330	the	time[114]	new[114]	_	_
14-3	2331-2339	meantime	time[114]	new[114]	_	_
14-4	2340-2341	(	_	_	_	_
14-5	2342-2345	the	abstract[116]	giv[116]	coref	16-10[136_116]
14-6	2346-2352	mental	abstract[116]	giv[116]	_	_
14-7	2353-2359	health	abstract|abstract[116]	giv|giv[116]	coref	14-27
14-8	2360-2366	review	abstract[116]	giv[116]	_	_
14-9	2367-2375	included	_	_	_	_
14-10	2376-2382	papers	object	new	_	_
14-11	2383-2385	up	_	_	_	_
14-12	2386-2388	to	_	_	_	_
14-13	2389-2396	October	time[118]	new[118]	_	_
14-14	2397-2401	2015	time[118]|time	new[118]|new	_	_
14-15	2402-2403	)	_	_	_	_
14-16	2404-2405	,	_	_	_	_
14-17	2406-2407	a	abstract[120]	new[120]	_	_
14-18	2408-2418	sufficient	abstract[120]	new[120]	_	_
14-19	2419-2425	number	abstract[120]	new[120]	_	_
14-20	2426-2428	of	abstract[120]	new[120]	_	_
14-21	2429-2432	new	abstract[120]|event[121]	new[120]|giv[121]	coref	15-1[128_121]
14-22	2433-2440	studies	abstract[120]|event[121]	new[120]|giv[121]	_	_
14-23	2441-2443	on	abstract[120]|event[121]	new[120]|giv[121]	_	_
14-24	2444-2448	more	abstract[120]|event[121]|event[123]	new[120]|giv[121]|giv[123]	coref	17-4[139_123]
14-25	2449-2455	severe	abstract[120]|event[121]|event[123]	new[120]|giv[121]|giv[123]	_	_
14-26	2456-2462	mental	abstract[120]|event[121]|event[123]	new[120]|giv[121]|giv[123]	_	_
14-27	2463-2469	health	abstract[120]|event[121]|abstract|event[123]	new[120]|giv[121]|giv|giv[123]	coref	14-36
14-28	2470-2478	outcomes	abstract[120]|event[121]|event[123]	new[120]|giv[121]|giv[123]	_	_
14-29	2479-2480	,	abstract[120]|event[121]|event[123]	new[120]|giv[121]|giv[123]	_	_
14-30	2481-2485	such	abstract[120]|event[121]|event[123]	new[120]|giv[121]|giv[123]	_	_
14-31	2486-2488	as	abstract[120]|event[121]|event[123]	new[120]|giv[121]|giv[123]	_	_
14-32	2489-2499	depression	abstract[120]|event[121]|event[123]|abstract|abstract[125]	new[120]|giv[121]|giv[123]|giv|giv[125]	coref	17-11
14-33	2500-2503	and	abstract[120]|event[121]|event[123]|abstract[125]	new[120]|giv[121]|giv[123]|giv[125]	_	_
14-34	2504-2509	other	abstract[120]|event[121]|event[123]|abstract[125]|abstract[127]	new[120]|giv[121]|giv[123]|giv[125]|giv[127]	coref	18-33[161_127]
14-35	2510-2516	mental	abstract[120]|event[121]|event[123]|abstract[125]|abstract[127]	new[120]|giv[121]|giv[123]|giv[125]|giv[127]	_	_
14-36	2517-2523	health	abstract[120]|event[121]|event[123]|abstract[125]|abstract|abstract[127]	new[120]|giv[121]|giv[123]|giv[125]|giv|giv[127]	coref	18-15
14-37	2524-2533	disorders	abstract[120]|event[121]|event[123]|abstract[125]|abstract[127]	new[120]|giv[121]|giv[123]|giv[125]|giv[127]	_	_
14-38	2534-2535	,	_	_	_	_
14-39	2536-2540	were	_	_	_	_
14-40	2541-2550	published	_	_	_	_
14-41	2551-2552	.	_	_	_	_

#Text=A few studies were of longitudinal design and improved the quality aspect of the evidence base .
15-1	2553-2554	A	event[128]	giv[128]	coref	16-19[138_128]
15-2	2555-2558	few	event[128]	giv[128]	_	_
15-3	2559-2566	studies	event[128]	giv[128]	_	_
15-4	2567-2571	were	_	_	_	_
15-5	2572-2574	of	_	_	_	_
15-6	2575-2587	longitudinal	abstract[129]	new[129]	_	_
15-7	2588-2594	design	abstract[129]	new[129]	_	_
15-8	2595-2598	and	_	_	_	_
15-9	2599-2607	improved	_	_	_	_
15-10	2608-2611	the	abstract[131]	new[131]	_	_
15-11	2612-2619	quality	abstract|abstract[131]	giv|new[131]	_	_
15-12	2620-2626	aspect	abstract[131]	new[131]	_	_
15-13	2627-2629	of	abstract[131]	new[131]	_	_
15-14	2630-2633	the	abstract[131]|abstract[133]	new[131]|new[133]	ana	16-2[134_133]
15-15	2634-2642	evidence	abstract[131]|abstract|abstract[133]	new[131]|giv|new[133]	_	_
15-16	2643-2647	base	abstract[131]|abstract[133]	new[131]|new[133]	_	_
15-17	2648-2649	.	_	_	_	_

#Text=With that in mind , we aimed to supplement the WHO review by providing a formal meta-analysis with these additional studies .
16-1	2650-2654	With	_	_	_	_
16-2	2655-2659	that	abstract[134]	giv[134]	_	_
16-3	2660-2662	in	abstract[134]	giv[134]	_	_
16-4	2663-2667	mind	abstract[134]	giv[134]	_	_
16-5	2668-2669	,	_	_	_	_
16-6	2670-2672	we	person	acc	_	_
16-7	2673-2678	aimed	_	_	_	_
16-8	2679-2681	to	_	_	_	_
16-9	2682-2692	supplement	_	_	_	_
16-10	2693-2696	the	abstract[136]	giv[136]	_	_
16-11	2697-2700	WHO	abstract[136]	giv[136]	_	_
16-12	2701-2707	review	abstract[136]	giv[136]	_	_
16-13	2708-2710	by	_	_	_	_
16-14	2711-2720	providing	_	_	_	_
16-15	2721-2722	a	abstract[137]	new[137]	coref	18-1[149_137]
16-16	2723-2729	formal	abstract[137]	new[137]	_	_
16-17	2730-2743	meta-analysis	abstract[137]	new[137]	_	_
16-18	2744-2748	with	abstract[137]	new[137]	_	_
16-19	2749-2754	these	abstract[137]|event[138]	new[137]|giv[138]	_	_
16-20	2755-2765	additional	abstract[137]|event[138]	new[137]|giv[138]	_	_
16-21	2766-2773	studies	abstract[137]|event[138]	new[137]|giv[138]	_	_
16-22	2774-2775	.	_	_	_	_

#Text=By restricting to more confined clinical outcomes , such as depression and anxiety , and the exposure to residential road traffic noise ( as the most prevalent type of traffic noise exposure ) too many analysis subsets can be avoided .
17-1	2776-2778	By	_	_	_	_
17-2	2779-2790	restricting	_	_	_	_
17-3	2791-2793	to	_	_	_	_
17-4	2794-2798	more	event[139]	giv[139]	coref	18-24[157_139]
17-5	2799-2807	confined	event[139]	giv[139]	_	_
17-6	2808-2816	clinical	event[139]	giv[139]	_	_
17-7	2817-2825	outcomes	event[139]	giv[139]	_	_
17-8	2826-2827	,	event[139]	giv[139]	_	_
17-9	2828-2832	such	event[139]	giv[139]	_	_
17-10	2833-2835	as	event[139]	giv[139]	_	_
17-11	2836-2846	depression	event[139]|abstract	giv[139]|giv	_	_
17-12	2847-2850	and	event[139]	giv[139]	_	_
17-13	2851-2858	anxiety	event[139]|abstract	giv[139]|giv	_	_
17-14	2859-2860	,	event[139]	giv[139]	_	_
17-15	2861-2864	and	event[139]	giv[139]	_	_
17-16	2865-2868	the	event[139]|abstract[142]	giv[139]|giv[142]	_	_
17-17	2869-2877	exposure	event[139]|abstract[142]	giv[139]|giv[142]	_	_
17-18	2878-2880	to	event[139]|abstract[142]	giv[139]|giv[142]	_	_
17-19	2881-2892	residential	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	coref	18-18[155_145]
17-20	2893-2897	road	event[139]|abstract[142]|object|abstract[145]	giv[139]|giv[142]|new|giv[145]	_	_
17-21	2898-2905	traffic	event[139]|abstract[142]|abstract|abstract[145]	giv[139]|giv[142]|new|giv[145]	coref	17-30
17-22	2906-2911	noise	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-23	2912-2913	(	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-24	2914-2916	as	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-25	2917-2920	the	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-26	2921-2925	most	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-27	2926-2935	prevalent	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-28	2936-2940	type	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-29	2941-2943	of	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-30	2944-2951	traffic	event[139]|abstract[142]|abstract[145]|abstract	giv[139]|giv[142]|giv[145]|giv	coref	18-18
17-31	2952-2957	noise	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-32	2958-2966	exposure	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-33	2967-2968	)	event[139]|abstract[142]|abstract[145]	giv[139]|giv[142]|giv[145]	_	_
17-34	2969-2972	too	abstract[148]	new[148]	_	_
17-35	2973-2977	many	abstract[148]	new[148]	_	_
17-36	2978-2986	analysis	abstract|abstract[148]	new|new[148]	_	_
17-37	2987-2994	subsets	abstract[148]	new[148]	_	_
17-38	2995-2998	can	_	_	_	_
17-39	2999-3001	be	_	_	_	_
17-40	3002-3009	avoided	_	_	_	_
17-41	3010-3011	.	_	_	_	_

#Text=The updated meta-analysis should add to the growing collection of up-to-date systematic reviews on health effects of traffic noise ( e. g. , birth outcomes , cardiovascular and metabolic disease , and behavioral/emotional disorders in youth ) .
18-1	3012-3015	The	abstract[149]	giv[149]	_	_
18-2	3016-3023	updated	abstract[149]	giv[149]	_	_
18-3	3024-3037	meta-analysis	abstract[149]	giv[149]	_	_
18-4	3038-3044	should	_	_	_	_
18-5	3045-3048	add	_	_	_	_
18-6	3049-3051	to	_	_	_	_
18-7	3052-3055	the	abstract[150]	new[150]	_	_
18-8	3056-3063	growing	abstract[150]	new[150]	_	_
18-9	3064-3074	collection	abstract[150]	new[150]	_	_
18-10	3075-3077	of	abstract[150]	new[150]	_	_
18-11	3078-3088	up-to-date	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
18-12	3089-3099	systematic	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
18-13	3100-3107	reviews	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
18-14	3108-3110	on	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
18-15	3111-3117	health	abstract[150]|abstract[151]|abstract|abstract[153]	new[150]|giv[151]|giv|new[153]	_	_
18-16	3118-3125	effects	abstract[150]|abstract[151]|abstract[153]	new[150]|giv[151]|new[153]	_	_
18-17	3126-3128	of	abstract[150]|abstract[151]|abstract[153]	new[150]|giv[151]|new[153]	_	_
18-18	3129-3136	traffic	abstract[150]|abstract[151]|abstract[153]|abstract|abstract[155]	new[150]|giv[151]|new[153]|giv|giv[155]	appos	18-27[0_155]
18-19	3137-3142	noise	abstract[150]|abstract[151]|abstract[153]|abstract[155]	new[150]|giv[151]|new[153]|giv[155]	_	_
18-20	3143-3144	(	_	_	_	_
18-21	3145-3147	e.	_	_	_	_
18-22	3148-3150	g.	_	_	_	_
18-23	3151-3152	,	_	_	_	_
18-24	3153-3158	birth	event|event[157]	new|giv[157]	_	_
18-25	3159-3167	outcomes	event[157]	giv[157]	_	_
18-26	3168-3169	,	_	_	_	_
18-27	3170-3184	cardiovascular	abstract	giv	appos	18-29[160_0]
18-28	3185-3188	and	_	_	_	_
18-29	3189-3198	metabolic	person|abstract[160]	new|giv[160]	_	_
18-30	3199-3206	disease	abstract[160]	giv[160]	_	_
18-31	3207-3208	,	_	_	_	_
18-32	3209-3212	and	_	_	_	_
18-33	3213-3233	behavioral/emotional	abstract[161]	giv[161]	_	_
18-34	3234-3243	disorders	abstract[161]	giv[161]	_	_
18-35	3244-3246	in	abstract[161]	giv[161]	_	_
18-36	3247-3252	youth	abstract[161]|person	giv[161]|new	_	_
18-37	3253-3254	)	_	_	_	_
18-38	3255-3256	.	_	_	_	_
